drugset / Trial / NCT01683682
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
NaSingle-groupOpen-labelTreatment
Summary
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
Timeline
- Start
- 2013-04
- Primary completion
- 2015-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 150 mg | Oral |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |